AC Immune (NASDAQ:ACIU) Shares Down 5.4% – Here’s What Happened
by Doug Wharley · The Cerbat GemAC Immune (NASDAQ:ACIU – Get Free Report) shares fell 5.4% during mid-day trading on Tuesday . The company traded as low as $3.28 and last traded at $3.32. 485,891 shares were traded during trading, an increase of 41% from the average session volume of 343,582 shares. The stock had previously closed at $3.51.
Analyst Upgrades and Downgrades
A number of analysts recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of AC Immune in a report on Wednesday, October 8th. BTIG Research restated a “buy” rating and issued a $8.00 target price on shares of AC Immune in a research note on Tuesday, November 4th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $10.00.
Check Out Our Latest Stock Report on AC Immune
AC Immune Price Performance
The company has a market capitalization of $333.36 million, a PE ratio of -3.95 and a beta of 1.62. The business’s 50 day simple moving average is $3.16 and its 200 day simple moving average is $2.80.
AC Immune (NASDAQ:ACIU – Get Free Report) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.02. The company had revenue of $1.18 million during the quarter, compared to analyst estimates of $0.81 million. AC Immune had a negative return on equity of 84.32% and a negative net margin of 1,642.89%. As a group, analysts anticipate that AC Immune will post -0.62 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently modified their holdings of the company. Private Advisor Group LLC purchased a new stake in shares of AC Immune in the 3rd quarter valued at about $48,000. Susquehanna International Group LLP acquired a new stake in shares of AC Immune in the 3rd quarter worth $63,000. Sei Investments Co. acquired a new stake in AC Immune in the second quarter valued at about $51,000. Acadian Asset Management LLC grew its holdings in AC Immune by 87.1% during the first quarter. Acadian Asset Management LLC now owns 371,177 shares of the company’s stock worth $679,000 after acquiring an additional 172,796 shares during the period. Finally, Assenagon Asset Management S.A. acquired a new position in AC Immune during the third quarter worth about $549,000. 51.36% of the stock is currently owned by hedge funds and other institutional investors.
About AC Immune
AC Immune AG is a clinical-stage biopharmaceutical company headquartered in Lausanne, Switzerland, with a subsidiary in Boston, Massachusetts. The company specializes in the discovery and development of therapeutics and diagnostics for neurodegenerative diseases, with a primary focus on Alzheimer’s disease, Parkinson’s disease and other protein misfolding disorders. AC Immune leverages proprietary platform technologies to identify and optimize candidates that target pathological protein aggregates.
Since its founding in 2003, AC Immune has advanced multiple programs into clinical development.